Cipla’s US manufacturing facility gets ‘No Action Indicated’ status from FDA
The US regulator issued the classification on November 17, following a four-day inspection of the manufacturing facility in New York
Editorial & Syndication Notice: This story has been syndicated or published by 360 NEWS in accordance with verified fair-use, official press dissemination, and original attribution protocols. All trademarks, photos, and referenced quotes remain the property of their respective owners. For editorial corrections, press inquiries, or rights notices, contact [email protected].

